Risks

Negative net debt to EBITDA and a current ratio near 1.2 suggest limited balance-sheet cushion, leaving PAVM less resilient than better-capitalized biotech peers if funding markets tighten.

An extremely negative interest coverage ratio indicates earnings are not supporting financing costs, which can pressure valuation and flexibility more than in peers with recurring operating cash flow.

A very long cash conversion cycle and elevated days of sales outstanding imply working-capital drag, reducing liquidity efficiency versus peers with faster cash realization and cleaner cash burn profiles.

Zero inventory and unusually high payables days point to supplier-funding dependence, which can help near-term liquidity but may be less durable than peers with stronger self-funded operations.

Opportunities

Low net debt relative to EBITDA provides some financial optionality, which can support development continuity better than more levered peers if capital access remains available.

A modest debt-to-equity ratio suggests leverage is contained versus highly indebted peers, reducing refinancing pressure and preserving flexibility for clinical or commercial milestones.

The current ratio above 1.0 indicates near-term obligations are covered, which is more supportive than peers already operating below liquidity thresholds in capital-intensive biotech.

Supplier-funding dynamics and minimal inventory can preserve cash in the short run, giving PAVM a working-capital advantage over peers that must finance larger operating buffers.

Overall Score

PAVM’s forward positioning is constrained by weak earnings coverage and liquidity efficiency, while modest leverage and near-term liquidity provide only limited peer-relative support.